Table 3.
Socio-demographic and clinical factors associated with pre-ART loss to follow-up at GUH
| |
|
Crude OR (95% CI) |
Adjusted+OR (95% CI) |
|||
|---|---|---|---|---|---|---|
| Variables | n total | n (%) | OR | 95% CI | OR | 95% CI |
| Gender |
1089 |
|
|
|
|
|
| Male |
|
439 (40.3) |
1.01 |
(0.78, 1.31) |
2.00 |
(1.15, 3.46)* |
| Female |
|
650 (59.7) |
1.00 |
|
1.00 |
|
| Age group |
1089 |
|
|
|
|
|
| 15-24 |
|
176 (16.2) |
1.00 |
|
1.00 |
|
| 25-34 |
|
498 (45.7) |
0.59 |
(0.41, 0.83)* |
0.80 |
(0.40, 1.61) |
| 35-44 |
|
283 (26.0) |
0.41 |
(0.28, 0.61)* |
0.63 |
(0.28, 1.41) |
| 44+ |
|
132 (12.1) |
0.37 |
(0.23, 0.61)* |
0.77 |
(0.30, 2.00) |
| Marital status |
1089 |
|
|
|
|
|
| Never married |
|
190 (17.4) |
1.00 |
|
1.00 |
|
| Married |
|
498 (45.7) |
0.62 |
(0.43, 0.87)* |
0.39 |
(0.19, 0.79)* |
| Divorced/separated |
|
319 (29.3) |
0.85 |
(0.59, 1.23) |
1.18 |
(0.57, 2.44) |
| Widow/er |
|
82 (7.5) |
0.54 |
(0.31, 0.95)* |
0.54 |
(0.18 , 1.68) |
| Educational status |
1089 |
|
|
|
|
|
| No education |
|
384 (35.3) |
1.00 |
|
1.00 |
|
| Primary |
|
288 (26.4) |
1.03 |
(0.75, 1.41) |
1.47 |
(0.78, 2.77) |
| Secondary & above |
|
417 (38.3) |
0.67 |
(0.50, 0.91)* |
0.88 |
(0.48, 1.63) |
| Disclosure of HIV+ status |
1089 |
|
|
|
|
|
| To spouse/family members only |
|
616 (56.6) |
1.00 |
|
1.00 |
|
| To relatives/friends only |
|
86 (7.9) |
0.90 |
(0.55, 1.47) |
0.38 |
(0.12, 1.19) |
| To spouse/family members & relatives/friends |
|
35 (3.2) |
1.14 |
(0.56, 2.35) |
1.47 |
(0.41, 5.32) |
| To no one |
|
352 (32.3) |
1.33 |
(1.01, 1.75)* |
0.65 |
(0.37, 1.14) |
| Place of residence |
1089 |
|
|
|
|
|
| Gondar |
|
796 (73.1) |
1.00 |
|
1.00 |
|
| Out of Gondar |
|
293 (26.9) |
0.89 |
(0.67, 1.18) |
1.07 |
(0.61, 1.87) |
| History of TB treatment |
1044 |
|
|
|
|
|
| Yes |
|
222 (21.3) |
1.00 |
|
1.00 |
|
| No |
|
822 (78.7) |
1.37 |
(0.99, 1.89) |
0.73 |
(0.39 , 1.35) |
| CD4 cell count/μl |
1076 |
|
|
|
|
|
| ≤ 200 |
|
611(56.8) |
1.00 |
|
1.00 |
|
| 201-250 |
|
111(10.3) |
2.48 |
(1.59, 3.87)* |
2.22 |
(0.95, 5.19) |
| 251-300 |
|
75 (7.0) |
2.38 |
(1.41, 4.02)* |
2.64 |
(1.05, 6.65)* |
| 301-350 |
|
64 (5.9) |
5.75 |
(3.37, 9.82)* |
5.21 |
(1.94, 13.99)* |
| > 350 |
|
215 (20.0) |
10.76 |
(7.52, 15.38)* |
12.10 |
(6.33, 23.12)* |
| WHO stage |
1070 |
|
|
|
|
|
| Stage I |
|
257 (24.0) |
2.10 |
(1.39, 3.15)* |
2.81 |
(1.15, 6.91)* |
| Stage II |
|
194 (18.1) |
1.29 |
(0.83, 2.01) |
1.75 |
(0.69, 4.45) |
| Stage III |
|
446 (41.7) |
0.82 |
(0.56, 1.21) |
1.72 |
(0.77, 3.81) |
| Stage IV |
|
173 (16.2) |
1.00 |
|
1.00 |
|
| Next appointment record |
1089 |
|
|
|
|
|
| Yes |
|
784 (72.0) |
1.00 |
|
1.00 |
|
| No | 305 (28.0) | 173.30 | (99.25, 302.61)* | 241.39 | (119.90, 485.97)* | |
OR: Odds Ratio, CI: Confidence Interval, * p≤0.05, +A total of 1015 subjects included in the adjusted model.